- Home
- SCD vs KOD Comparison
SCD vs KOD Comparison
Compare SCD & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- KOD
- Stock Information
- Founded
- SCD 2003
- KOD 2009
- Country
- SCD United States
- KOD United States
- Employees
- SCD N/A
- KOD N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCD Finance
- KOD Health Care
- Exchange
- SCD Nasdaq
- KOD Nasdaq
- Market Cap
- SCD 248.0M
- KOD 259.6M
- IPO Year
- SCD N/A
- KOD 2018
- Fundamental
- Price
- SCD $16.12
- KOD $3.40
- Analyst Decision
- SCD
- KOD Hold
- Analyst Count
- SCD 0
- KOD 3
- Target Price
- SCD N/A
- KOD $9.00
- AVG Volume (30 Days)
- SCD 62.6K
- KOD 440.1K
- Earning Date
- SCD 01-01-0001
- KOD 05-14-2025
- Dividend Yield
- SCD 9.63%
- KOD N/A
- EPS Growth
- SCD N/A
- KOD N/A
- EPS
- SCD N/A
- KOD N/A
- Revenue
- SCD N/A
- KOD N/A
- Revenue This Year
- SCD N/A
- KOD N/A
- Revenue Next Year
- SCD N/A
- KOD N/A
- P/E Ratio
- SCD N/A
- KOD N/A
- Revenue Growth
- SCD N/A
- KOD N/A
- 52 Week Low
- SCD $11.33
- KOD $1.92
- 52 Week High
- SCD $15.87
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- SCD 63.98
- KOD 45.30
- Support Level
- SCD $15.49
- KOD $3.46
- Resistance Level
- SCD $15.99
- KOD $3.81
- Average True Range (ATR)
- SCD 0.28
- KOD 0.42
- MACD
- SCD 0.03
- KOD -0.07
- Stochastic Oscillator
- SCD 92.86
- KOD 34.50
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.